Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 1134 of 3330
Next
>>
>
28326 to 28350 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
MB 157	Unknown	Unknown	Gefitinib	EGFR	ErbB	0.00213	uM	9039.016	0.9251	0.7344	0.5468
MB 157	Unknown	Unknown	Gefitinib	EGFR	ErbB	0.0107	uM	9039.016	1.0237	1.0874	0.5468
MB 157	Unknown	Unknown	Gefitinib	EGFR	ErbB	0.0533	uM	9039.016	0.9528	0.8306	0.5468
MB 157	Unknown	Unknown	Gefitinib	EGFR	ErbB	0.267	uM	9039.016	0.9230	0.7275	0.5468
MB 157	Unknown	Unknown	Gefitinib	EGFR	ErbB	1.33	uM	9039.016	0.9313	0.7558	0.5468
MB 157	Unknown	Unknown	Gefitinib	EGFR	ErbB	6.67	uM	9039.016	0.8016	0.3345	0.5468
MB 157	Unknown	Unknown	Gefitinib	EGFR	ErbB	33.3	uM	9039.016	0.4227	-0.5859	0.5468
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.0000853	uM	7867.016	1.0189	1.0166	2.2657
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.000427	uM	7867.016	1.0916	1.0789	2.2657
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.00213	uM	7867.016	0.9634	0.9674	2.2657
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.0107	uM	7867.016	1.0492	1.0428	2.2657
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.0533	uM	7867.016	0.9859	0.9875	2.2657
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.267	uM	7867.016	0.9290	0.9360	2.2657
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	1.33	uM	7867.016	0.2040	-0.0083	2.2657
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	6.67	uM	7867.016	0.1433	-0.1516	2.2657
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	33.3	uM	7867.016	0.0451	-0.4905	2.2657
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.0000853	uM	7868.016	1.0493	1.0464	2.0998
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.000427	uM	7868.016	0.9702	0.9714	2.0998
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.00213	uM	7868.016	0.9310	0.9330	2.0998
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.0107	uM	7868.016	1.0175	1.0165	2.0998
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.0533	uM	7868.016	1.0793	1.0740	2.0998
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	0.267	uM	7868.016	1.0336	1.0317	2.0998
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	1.33	uM	7868.016	0.2530	0.0395	2.0998
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	6.67	uM	7868.016	0.1404	-0.2149	2.0998
MCF 10A	NM	Basal B	Gefitinib	EGFR	ErbB	33.3	uM	7868.016	0.0059	-0.8265	2.0998

|<
<<
Previous
Page 1134 of 3330
Next
>>
>
28326 to 28350 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)